Development of cancer therapeutic technology by functional measurement and control of cell division.

本公司开发了利用发现的癌症标志物Bradeion进行癌症早期诊断和治疗监测的技术。此外，还开发了用于发现抗癌剂的Bradeion测定技术。结果，我们成功地开发了癌症诊断系统和试剂盒。此外，我们还成功地进行了Bradeion的结构分析和表征，并通过建立其酶活性测定方法，开发了测定其抑制效果的技术。在研究期的最后一年，我们使用荧光相关光谱（FCS）检测患者血清中的单个靶分子。这是一台配备激光共聚焦显微镜的全自动仪器，可在1分钟内使用10 pI血清进行测量，每个样本的成本仅为1日元。可在一周内测量3000个样品。在室温下储存一周的样品中，数据是可重现的。样品在冰箱中保存一个月是稳定的，直到现在，尽管许多蛋白质结构分析的项目泛滥，但一种具有独创性的材料的结构呈现毕竟没有成功。另一方面，我们成功地进行了癌症标志物Bradeion的结构分析，因此我们将范围缩小到只有一种有用的材料，并集中了符合目的的方法。抗癌药物的筛选不仅要考虑药物的疗效，而且要考虑药物的毒性。因此，我们使用果蝇和嵌合小鼠（专利）配备了用于毒性检查的动物模型。我们从Bradeion蛋白的结构分析中研究了一种抑制剂，并使用FCS进行了高通量筛选。我们的目标是开发一种抗癌剂，通过评估筛选和动物模型的毒性检查选择的候选人。

We have developed a technology for early diagnosis and cure monitor of cancer with Bradeion, a cancer marker we found. We have also developed the technology of Bradeion assay for discovering anticancer agent. As a result, we succeeded in the development of a cancer diagnosis system and kit. In addition, we succeeded in the structure analysis and the characterization of Bradeion, and development of the technology measuring inhibiting effect by the establishment of the method measuring its enzyme activity. In the last year of the study period, we used a fluorescence correlation spectroscopy (FCS) detecting single target molecule in patient serum. This full automatic machine with confocal laser microscope can measure using 10 pI of serum with a minute, and it costs only \1 per specimen. 3, 000 samples can be measured within one week. The data is reproducible in the samples stored at room temperature for a week. The samples preserved in a refrigerator are stable for a month.The structure presentation of a material with originality did not succeed after all until now, though many projects for protein structure analysis flooded. On the other hand, we succeed in the structure analysis of the cancer marker, Bradeion, as a result that we narrowed down to only one useful material and centralized the methodology that complies with a purpose. It is not only medicinal benefits but also less toxicity that is important to select the candidate of and cancer drug. We therefore equipped animal models for the toxic examination using a Drosophila and a chimera mouse(patented). We investigate an inhibitor from structure analysis of Bradeion protein and perform a high throughput screening using the FCS. We aim at development of an anticancer agent, by performing the evaluation of the candidate selected by the screening and a toxic examination by the animal model.